Surrozen (SRZN) Corporate presentation summary

Market opportunity and unmet needs

• Retinal vascular diseases like DME and wet AMD affect over 40 million globally, with a projected anti-VEGF market size exceeding $20B by 2030 and a CAGR of ~10%.

• Current therapies have limitations, including the need for better drying agents, longer-lasting effects, and alternatives to VEGF inhibition.

Scientific rationale and innovation

• Combining complementary mechanisms of action (MOAs) such as Wnt activation, VEGF inhibition, and IL-6 inhibition is supported by clinical and genetic evidence for superior outcomes.

• Wnt signaling is essential for retinal vascular integrity; Wnt mimetics restore vascular function and show efficacy comparable to anti-VEGF in preclinical and early clinical studies.

• Multi-functional antibodies targeting Wnt, VEGF, and IL-6 are designed to address unmet needs and demonstrate synergy in preclinical models.

Pipeline and product candidates

• SZN-413, a first-in-class FZD4/LRP5 bi-specific antibody, activates Wnt signaling and is licensed to Boehringer Ingelheim with $12.5M upfront and up to $586.5M in milestones.

• SZN-8141 combines Wnt activation and VEGF inhibition, showing 80% reduction in avascular area and comparable VEGF binding to aflibercept.

• SZN-8143 adds IL-6 inhibition to Wnt and VEGF targeting, aiming for additional benefit in uveitic and other retinal vascular diseases.